Tetraphase and Everest agree licensing deal in Asia for novel antibiotic

21 February 2018

Massachusetts, USA-based Tetraphase Pharmaceuticals (Nasdaq: TTPH) has sold the rights to eravacycline, a novel, fully-synthetic fluorocycline antibiotic, to Shanghai and Beijing-based Everest Medicines.

The Chinese firm gains the exclusive rights to develop, seek regulatory approval for, and commercialize the product in China, Hong Kong, Taiwan and South Korea.

Tetraphase, which is focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, will be paid $7 million upfront, and will be eligible to receive clinical and regulatory milestones of up to $16.5 million as well as annual sales milestones of up to $20 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK